A Comprehensive Prognostic and Immunological Analysis of a New Three-Gene Signature in Hepatocellular Carcinoma

Table 1

Patients’ information in the TCGA and ICGC cohorts.

Clinical characteristics		Total	%
TCGA		370
Survival status	Survival	244	65.95
	Death	126	34.05
Age	≤65years	232	62.70
	>65 years	138	37.30
Gender	Male	249	67.30
	Female	121	32.70
Histological grade	G1	55	14.86
	G2	177	47.84
	G3	121	32.70
	G4	12	3.24
Stage	I	171	46.22
	II	85	22.97
	III	85	22.97
	IV	5	1.35
T classification	T1	181	48.92
	T2	93	25.14
	T3	80	21.62
	T4	13	3.51
	TX	1	0.27
M classification	M0	266	71.89
	M1	4	1.08
	MX	100	27.03
N classification	N0	252	68.11
	N1	4	1.08
	NX	113	30.54
ICGC		232
Survival status	Survival	189	81.47
	Death	43	18.53
Age	≤65 years	90	38.79
	>65 years	142	61.21
Gender	Male	171	73.71
	Female	61	26.29
Stage	I	36	15.52
	II	106	45.69
	III	71	30.60
	IV	19	8.19
Prior malignancy	No	202	87.07
	Yes	30	12.93